Persistence with Insulin Glargine 300 IU/ml Compared with Other Basal Insulins—A Canadian Retrospective Cohort Study
Bibliographic record
Abstract
Introduction: Insulin glargine (300 units/mL) is a long-acting insulin approved in Canada on 28-May-2015 for once-daily administration in the treatment of T1DM or T2DM requiring basal insulin therapy. Made of the identical molecule as insulin glargine (100 unit/mL), insulin glargine (300 units/mL) delivers the same amount of insulin in one third of the dose. Four pivotal trials compared GLA-300 to GLA-100 with changes in HbA1C from baseline to 6 months. However, persistence is another important medication metric. Persistence with antihyperglycemic therapies have been associated with positive clinical outcomes and reduced health care costs. Objective: To assess 12-month persistence on neutral protamine Hagedorn (NPH), insulin detemir, and insulin glargine using Canadian private claims data. Methods: The study utilized longitudinal private drug plan claims data from IQVIA’s Canadian Private Drug Plan Database. The study was performed looking at persistence for T1DM and T2DM patients combined, without any treatment cessation or change to a different basal insulin. Patients were indexed on their first claim for any of the basal insulins of interest between May 28th 2014 and June 30th 2016, patients’ basal insulin therapy was tracked for 12 months plus a 3 month look-forward period. Patients who did not have continuous coverage or with fewer than 3 claims for an insulin were excluded from the analysis. Results: At 12 months using a 90 day grace period, 63% of insulin glargine 300 IU/ ml (Toujeo®) patients persisted with therapy compared to 54% of insulin glargine 100 IU/ml (Basaglar), 50% for insulin glargine 100 IU/ml (Lantus), 45% insulin detemir 100 IU/ml (Levemir) and 29% of NPH patients. Conclusion: A retrospective cohort study of real-world claims data demonstrated insulin glargine 300 IU/ml (Toujeo ®) had the highest persistence among all basal insulins. Disclosure K.A. Quansah: Consultant; Self; Sanofi. Employee; Self; Allergan. L. Sauriol: Employee; Self; Sanofi. A.A. Kukaswadia: Consultant; Self; Sanofi. S. Bremner: Consultant; Self; Sanofi. B. Millson: Consultant; Self; Sanofi.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Direct model labels (unvalidated)
Per-model category and study-design labels from the labeling rounds. They are machine output, unvalidated, and the disagreement between models ships as data. No study design here is MEDLINE-validated yet.
| Model arm | Categories | Study design | Confidence |
|---|---|---|---|
| gemma | no category Domain: not available · Genre: Empirical About the Canadian research system: no · About a Canadian topic: no | Observational | low |
| gpt | no category Domain: not available · Genre: Empirical About the Canadian research system: no · About a Canadian topic: no | Observational | high |
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.002 | 0.006 |
| Science and technology studies | 0.003 | 0.001 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedLabeled directly by 2 models reading the full record.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".